The Medical Advisor

Here’s a concise and evidence-based overview of Ivermectin, Fenbendazole, Mebendazole, and their potential relationship to Multiple Myeloma (MM), a cancer of plasma cells, as of March 26, 2025. This response draws on recent studies and anecdotal reports while acknowledging the current limitations of the evidence. Ivermectin and Multiple Myeloma Ivermectin, an FDA-approved antiparasitic drug, has shown preclinical promise against MM: 2024 Study (Yang Song et al.) : Published in World Journal of Clinical Oncology , this study assessed Ivermectin’s potential against the high-risk t(4;14) MM subtype. Using bioinformatics, molecular docking, and in vitro experiments, it found Ivermectin inhibited MM cell growth and induced apoptosis via the NF-κB signaling pathway. Key genes linked to this subtype were identified, suggesting Ivermectin as a candidate for repurposing. 2023 Study (PubMed) : Ivermectin synergized with proteasome inhibitors (e.g., bortezomib) in vitro and in vivo, inhibiting p...

Introduction: A Turning Point in Multiple Myeloma (2026) The treatment landscape for multiple myeloma has undergone a dramatic transformation between 2021 and 2026. What was once a disease dominated by sequential chemotherapy and monoclonal antibodies is now entering the era of cellular therapy and T-cell–redirecting immunotherapy . Two modalities are now reshaping outcomes: CAR-T cell therapy (chimeric antigen receptor T cells) Bispecific antibodies (T-cell engagers) Both target key antigens such as BCMA (B-cell maturation antigen) and GPRC5D , enabling the immune system to directly eliminate malignant plasma cells. But a critical question remains: 👉 Which is better—CAR-T or bispecific antibodies? And when should each be used? This guide synthesizes the latest 2026 clinical data, dosing protocols, and real-world insights into a practical, SEO-optimized resource. The Evolution of Myeloma Treatment (2021–2026) From Late-Line Rescue to Early-Line Strategy Between 2021 and 2022: CAR-T t...